Shots:

• The P-III study evaluates the efficacy- safety & immunogenicity of BCD-021 (q3w for 6 cycles) vs reference Avastin + paclitaxel & carboplatin in 357 patients with stage IIIB or IV nonsq. NSCLC across Russia- Belarus- Ukraine & India
• The study showed an equivalent efficacy- ORR (34.6% & 33.8%)- 341 patients had 1 CT scan after initiation of treatment- patients achieved stable disease (31.7% & 33.8%); CR (1.5% & 0.7%); PR (33.2% & 33.1%) @18wks. & continue with BCD-021 until disease progression- death- or unacceptable toxicity
• Patients experienced AEs (91.3% vs 93.4%); serious AEs (13.6% vs 10.9%)- treatment discontinuation due to AEs- treatment-related serious AEs (3.4% vs 2.2%)- respectively

  | Ref: Biocad | Image: Businesswire